Practice Points:
- Clinicians looking after neonates with NE treated with TH must be aware of SFNN and must be assessed the neonates routinely for SFNN
- Routine clinical and biochemical monitoring for hypercalcemia in those with SFNN or at-risk is critical
- Hypercalcemia is typically detected at a month of age; half the neonates are asymptomatic
- Prompt intervention often including hospitalization reduces morbidity and mortality
- Treatment may include low calcium-vitamin D formula or bisphosphonates with supervision by pediatric endocrinology
To view the full text and an associated presentation, become a NBS member here